|
|
Article: Somaxon Pharmaceuticals, Inc. Initiates Second Phase III Clinical Trial of SILENOR(TM) -- Product will be evaluated in long-term trial of elderly patients with primary chronic insomnia.
- Article from:
- Business Wire
- Article date:
- September 20, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that enrollment has begun in the second Phase III clinical trial of SILENOR(TM) (doxepin hydrochloride) for the treatment of insomnia. This multi-center, placebo-controlled Phase III clinical trial will evaluate the safety and efficacy of SILENOR(TM) over a three month period in elderly patients diagnosed with primary chronic insomnia. The primary endpoint of the trial is Wake After Sleep Onset (WASO), the ...